{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T21:39:38Z","timestamp":1790285978212,"version":"4.1.0"},"reference-count":39,"publisher":"Oxford University Press (OUP)","issue":"8","license":[{"start":{"date-parts":[[2021,6,11]],"date-time":"2021-06-11T00:00:00Z","timestamp":1623369600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,10,20]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Mycobacterium abscessus subsp. abscessus is one of the most difficult pathogens to treat and its incidence in disease is increasing. Dual \u03b2-lactam combinations act synergistically in vitro but are not widely employed in practice. A recent study shows that a combination of imipenem and ceftaroline significantly lowers the minimum inhibitory concentration of clinical isolates, despite both drugs targeting the same peptidoglycan synthesis enzymes. The underlying mechanism of this effect provides a basis for further investigations of dual \u03b2-lactam combinations in the treatment of M. abscessus subsp. abscessus, eventually leading to a clinical trial. Furthermore, dual \u03b2-lactam strategies may be explored for other difficult mycobacterial infections.<\/jats:p>","DOI":"10.1093\/cid\/ciab535","type":"journal-article","created":{"date-parts":[[2021,6,8]],"date-time":"2021-06-08T15:45:14Z","timestamp":1623167114000},"page":"1532-1536","source":"Crossref","is-referenced-by-count":42,"title":["\u201cOne-Two Punch\u201d: Synergistic \u00df-Lactam Combinations for\n                    <i>Mycobacterium abscessus<\/i>\n                    and Target Redundancy in the Inhibition of Peptidoglycan Synthesis Enzymes"],"prefix":"10.1093","volume":"73","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5738-2976","authenticated-orcid":false,"given":"David C","family":"Nguyen","sequence":"first","affiliation":[{"name":"Division of Infectious Diseases and HIV Medicine, University Hospitals Cleveland Medical Center, Cleveland, Ohio, USA"},{"name":"Division of Pediatric Infectious Diseases, Rainbow Babies and Children\u2019s Hospital, University Hospitals Cleveland Medical Center, Cleveland, Ohio, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Khalid M","family":"Dousa","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine and Infectious Diseases, Louis Stokes Cleveland Department of Veterans Affairs Medical Center, Cleveland, Ohio, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sebastian G","family":"Kurz","sequence":"additional","affiliation":[{"name":"Mount Sinai National Jewish Respiratory Institute, New York, New York, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sheldon T","family":"Brown","sequence":"additional","affiliation":[{"name":"Department of Medicine, Icahn School of Medicine at Mount Sinai, New York, New York, USA"},{"name":"Department of Medicine, James J. Peters VA Medical Center, Bronx, New York, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George","family":"Drusano","sequence":"additional","affiliation":[{"name":"Institute for Therapeutic Innovation, University of Florida, Orlando, Florida, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven M","family":"Holland","sequence":"additional","affiliation":[{"name":"Laboratory of Clinical Immunology and Microbiology, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barry N","family":"Kreiswirth","sequence":"additional","affiliation":[{"name":"Center for Discovery and Innovation, Hackensack Meridian Health, Nutley, New Jersey, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"W Henry","family":"Boom","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases and HIV Medicine, University Hospitals Cleveland Medical Center, Cleveland, Ohio, USA"},{"name":"Tuberculosis Research Unit, Case Western Reserve University, Cleveland, Ohio, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles L","family":"Daley","sequence":"additional","affiliation":[{"name":"Division of Mycobacterial and Respiratory Infections, National Jewish Health, Denver, Colorado, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert A","family":"Bonomo","sequence":"additional","affiliation":[{"name":"Department of Medicine, Pharmacology, Molecular Biology and Microbiology, Biochemistry, Proteomics, and Bioinformatics, Case Western Reserve University School of Medicine, Cleveland, Ohio, USA"},{"name":"Medical Service, Research Service, and Geriatric Research Education and Clinical Centers (GRECC), Louis Stokes Cleveland Department of Veterans Affairs Medical Center, Cleveland, Ohio, USA"},{"name":"Case Western Reserve University (CWRU)-Cleveland VAMC Center for Antimicrobial Resistance and Epidemiology, Cleveland, Ohio, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2021,6,11]]},"reference":[{"key":"2021121702383980400_CIT0001","doi-asserted-by":"crossref","first-page":"e00098-20","DOI":"10.1128\/AAC.00098-20","article-title":"Insights into the L,D-transpeptidases and D,D-carboxypeptidase of Mycobacterium abscessus: ceftaroline, imipenem, and novel diazabicyclooctane inhibitors","volume":"64","author":"Dousa","year":"2020","journal-title":"Antimicrob Agents Chemother"},{"key":"2021121702383980400_CIT0002","doi-asserted-by":"crossref","first-page":"4471","DOI":"10.1099\/ijsem.0.001376","article-title":"Emended description of Mycobacterium abscessus, Mycobacterium abscessus subsp. abscessus and Mycobacterium abscessus subsp. bolletii and designation of Mycobacterium abscessus subsp. massiliense comb. nov","volume":"66","author":"Tortoli","year":"2016","journal-title":"Int J Syst Evol Microbiol"},{"key":"2021121702383980400_CIT0003","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.ccm.2014.10.002","article-title":"Epidemiology of human pulmonary infection with nontuberculous mycobacteria: a review","volume":"36","author":"Prevots","year":"2015","journal-title":"Clin Chest Med"},{"key":"2021121702383980400_CIT0004","doi-asserted-by":"crossref","first-page":"e01206-17","DOI":"10.1128\/AAC.01206-17","article-title":"Systemic review and meta-analyses of the effect of chemotherapy on pulmonary Mycobacterium abscessus outcome and disease recurrence","volume":"61","author":"Pasipanodya","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"2021121702383980400_CIT0005","doi-asserted-by":"crossref","first-page":"1638","DOI":"10.3201\/2109.141634","article-title":"Mycobacterium abscessus complex infections in humans","volume":"21","author":"Lee","year":"2015","journal-title":"Emerg Infect Dis"},{"key":"2021121702383980400_CIT0006","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.jcf.2009.12.001","article-title":"Chronic Mycobacterium abscessus infection and lung function decline in cystic fibrosis","volume":"9","author":"Esther","year":"2010","journal-title":"J Cyst Fibros"},{"key":"2021121702383980400_CIT0007","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1056\/NEJMoa1111160","article-title":"Adult-onset immunodeficiency in Thailand and Taiwan","volume":"367","author":"Browne","year":"2012","journal-title":"N Engl J Med"},{"key":"2021121702383980400_CIT0008","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1093\/jac\/dkr578","article-title":"Mycobacterium abscessus: a new antibiotic nightmare","volume":"67","author":"Nessar","year":"2012","journal-title":"J Antimicrob Chemother"},{"key":"2021121702383980400_CIT0009","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1093\/cid\/ciaa241","article-title":"Treatment of nontuberculous mycobacterial pulmonary disease: an official ATS\/ERS\/ESCMID\/IDSA clinical practice guideline","volume":"71","author":"Daley","year":"2020","journal-title":"Clin Infect Dis"},{"key":"2021121702383980400_CIT0010","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1128\/AAC.01275-08","article-title":"A novel gene, erm(41), confers inducible macrolide resistance to clinical isolates of Mycobacterium abscessus but is absent from Mycobacterium chelonae","volume":"53","author":"Nash","year":"2009","journal-title":"Antimicrob Agents Chemother"},{"key":"2021121702383980400_CIT0011","doi-asserted-by":"crossref","first-page":"2606","DOI":"10.1093\/jac\/dks279","article-title":"Acquisition of clarithromycin resistance mutations in the 23S rRNA gene of Mycobacterium abscessus in the presence of inducible erm(41)","volume":"67","author":"Maurer","year":"2012","journal-title":"J Antimicrob Chemother"},{"key":"2021121702383980400_CIT0012","doi-asserted-by":"crossref","first-page":"2273","DOI":"10.3389\/fmicb.2018.02273","article-title":"Mycobacterium abscessus and \u03b2-lactams: emerging insights and potential opportunities","volume":"9","author":"Story-Roller","year":"2018","journal-title":"Front Microbiol"},{"key":"2021121702383980400_CIT0013","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1093\/jac\/dkt410","article-title":"Characterization of broad-spectrum Mycobacterium abscessus class A \u03b2-lactamase","volume":"69","author":"Soroka","year":"2014","journal-title":"J Antimicrob Chemother"},{"key":"2021121702383980400_CIT0014","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1186\/s13756-018-0448-4","article-title":"The addition of avibactam renders piperacillin an effective treatment for Mycobacterium abscessus infection in an in vivo model","volume":"7","author":"Meir","year":"2018","journal-title":"Antimicrob Resist Infect Control"},{"key":"2021121702383980400_CIT0015","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1093\/jac\/dku510","article-title":"\u03b2-Lactamase inhibition by avibactam in Mycobacterium abscessus","volume":"70","author":"Dub\u00e9e","year":"2015","journal-title":"J Antimicrob Chemother"},{"key":"2021121702383980400_CIT0016","doi-asserted-by":"crossref","first-page":"2938","DOI":"10.1128\/AAC.05080-14","article-title":"Impact of \u03b2-lactamase inhibition on the activity of ceftaroline against Mycobacterium tuberculosis and Mycobacterium abscessus","volume":"59","author":"Dub\u00e9e","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"2021121702383980400_CIT0017","doi-asserted-by":"crossref","first-page":"e02440-16","DOI":"10.1128\/AAC.02440-16","article-title":"Inhibition of the beta-lactamase BlaMab by avibactam improves in vitro and in vivo efficacy of imipenem against Mycobacterium abscessus","volume":"61","author":"Lefebvre","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"2021121702383980400_CIT0018","doi-asserted-by":"crossref","first-page":"e01915-18","DOI":"10.1128\/AAC.01915-18","article-title":"In vitro and intracellular activity of imipenem combined with tedizolid, rifabutin, and avibactam against Mycobacterium abscessus","volume":"63","author":"Le Run","year":"2019","journal-title":"Antimicrob Agents Chemother"},{"key":"2021121702383980400_CIT0019","doi-asserted-by":"crossref","first-page":"e00733-19","DOI":"10.1128\/AAC.00733-19","article-title":"New \u03b2-lactamase inhibitors nacubactam and zidebactam improve the in vitro activity of \u03b2-lactam antibiotics against Mycobacterium abscessus complex clinical isolates","volume":"63","author":"Kaushik","year":"2019","journal-title":"Antimicrob Agents Chemother"},{"key":"2021121702383980400_CIT0020","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1128\/JB.00606-10","article-title":"The peptidoglycan of Mycobacterium abscessus is predominantly cross-linked by L,D-transpeptidases","volume":"193","author":"Lavollay","year":"2011","journal-title":"J Bacteriol"},{"key":"2021121702383980400_CIT0021","doi-asserted-by":"crossref","first-page":"e00866-17","DOI":"10.1128\/AAC.00866-17","article-title":"Mycobacterium abscessus L,D-transpeptidases are susceptible to inactivation by carbapenems and cephalosporins but not penicillins","volume":"61","author":"Kumar","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"2021121702383980400_CIT0022","doi-asserted-by":"crossref","first-page":"e02613-18","DOI":"10.1128\/AAC.02613-18","article-title":"Select beta-lactam combinations exhibit synergy against Mycobacterium abscessus in vitro","volume":"63","author":"Story-Roller","year":"2019","journal-title":"Antimicrob Agents Chemother"},{"key":"2021121702383980400_CIT0023","doi-asserted-by":"crossref","DOI":"10.1128\/mBio.02895-18","article-title":"Dual beta-lactam combinations highly active against Mycobacterium abscessus complex in vitro","volume":"10","author":"Pandey","year":"2019","journal-title":"mBio"},{"key":"2021121702383980400_CIT0024","doi-asserted-by":"crossref","first-page":"1984","DOI":"10.1128\/AAC.39.9.1984","article-title":"Synergistic effect of amoxicillin and cefotaxime against Enterococcus faecalis","volume":"39","author":"Mainardi","year":"1995","journal-title":"Antimicrob Agents Chemother"},{"key":"2021121702383980400_CIT0025","doi-asserted-by":"crossref","first-page":"1435","DOI":"10.1161\/CIR.0000000000000296","article-title":"Infective endocarditis in adults: diagnosis, antimicrobial therapy, and management of complications: a scientific statement for healthcare professionals from the American Heart Association","volume":"132","author":"Baddour","year":"2015","journal-title":"Circulation"},{"key":"2021121702383980400_CIT0026","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1128\/AAC.02102-15","article-title":"Distinctive binding of avibactam to penicillin-binding proteins of gram-negative and gram-positive bacteria","volume":"60","author":"Asli","year":"2016","journal-title":"Antimicrob Agents Chemother"},{"key":"2021121702383980400_CIT0027","doi-asserted-by":"crossref","first-page":"8081","DOI":"10.1002\/chem.201800923","article-title":"Synthesis of avibactam derivatives and activity on \u03b2-lactamases and peptidoglycan biosynthesis enzymes of mycobacteria","volume":"24","author":"Edoo","year":"2018","journal-title":"Chemistry"},{"key":"2021121702383980400_CIT0028","doi-asserted-by":"crossref","first-page":"3690","DOI":"10.1038\/s41598-020-60452-1","article-title":"A mouse model of pulmonary Mycobacteroides abscessus infection","volume":"10","author":"Maggioncalda","year":"2020","journal-title":"Sci Rep"},{"key":"2021121702383980400_CIT0029","doi-asserted-by":"crossref","first-page":"e00614-19","DOI":"10.1128\/AAC.00614-19","article-title":"Synergistic efficacy of \u03b2-lactam combinations against Mycobacterium abscessus pulmonary infection in mice","volume":"8","author":"Story-Roller","year":"2019","journal-title":"Antimicrob Agents Chemother"},{"key":"2021121702383980400_CIT0030","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1053\/j.semdp.2017.04.006","article-title":"HIV and mycobacteria","volume":"34","author":"Procop","year":"2017","journal-title":"Semin Diagn Pathol"},{"key":"2021121702383980400_CIT0031","volume-title":"Global tuberculosis report 2020","author":"World Health Organization","year":"2020"},{"key":"2021121702383980400_CIT0032","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1016\/j.idc.2020.06.001","article-title":"Drug-resistant tuberculosis: a glance at progress and global challenges","volume":"34","author":"Dousa","year":"2020","journal-title":"Infect Dis Clin North Am"},{"key":"2021121702383980400_CIT0033","doi-asserted-by":"crossref","first-page":"4360","DOI":"10.1128\/JB.00239-08","article-title":"The peptidoglycan of stationary-phase Mycobacterium tuberculosis predominantly contains cross-links generated by L,D-transpeptidation","volume":"190","author":"Lavollay","year":"2008","journal-title":"J Bacteriol"},{"key":"2021121702383980400_CIT0034","doi-asserted-by":"crossref","first-page":"11998","DOI":"10.1021\/bi701506h","article-title":"Irreversible inhibition of the Mycobacterium tuberculosis beta-lactamase by clavulanate","volume":"46","author":"Hugonnet","year":"2007","journal-title":"Biochemistry"},{"key":"2021121702383980400_CIT0035","volume-title":"WHO consolidated guidelines on drug-resistant tuberculosis treatment","author":"World Health Organization","year":"2019"},{"key":"2021121702383980400_CIT0036","doi-asserted-by":"crossref","first-page":"e92","DOI":"10.1164\/rccm.201909-1874ST","article-title":"Treatment of drug-resistant tuberculosis: an official ATS\/CDC\/ERS\/IDSA clinical practice guideline","volume":"200","author":"Nahid","year":"2019","journal-title":"Am J Respir Crit Care"},{"key":"2021121702383980400_CIT0037","doi-asserted-by":"crossref","first-page":"2816","DOI":"10.1128\/AAC.49.7.2816-2821.2005","article-title":"Imipenem for treatment of tuberculosis in mice and humans","volume":"49","author":"Chambers","year":"2005","journal-title":"Antimicrob Agents Chemother"},{"key":"2021121702383980400_CIT0038","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1056\/NEJMc1513236","article-title":"\u03b2-Lactams against tuberculosis\u2014new trick for an old dog?","volume":"375","author":"Diacon","year":"2016","journal-title":"N Engl J Med"},{"key":"2021121702383980400_CIT0039","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1164\/rccm.201911-2149LE","article-title":"Optimizing \u03b2-lactams against tuberculosis","volume":"201","author":"de Jager","year":"2020","journal-title":"Am J Respir Crit Care Med"}],"container-title":["Clinical Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/cid\/advance-article-pdf\/doi\/10.1093\/cid\/ciab535\/39310030\/ciab535.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/cid\/article-pdf\/73\/8\/1532\/41795152\/ciab535.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/cid\/article-pdf\/73\/8\/1532\/41795152\/ciab535.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,30]],"date-time":"2022-12-30T05:11:21Z","timestamp":1672377081000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/cid\/article\/73\/8\/1532\/6296402"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6,11]]},"references-count":39,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2021,6,11]]},"published-print":{"date-parts":[[2021,10,20]]}},"URL":"https:\/\/doi.org\/10.1093\/cid\/ciab535","relation":{},"ISSN":["1058-4838","1537-6591"],"issn-type":[{"value":"1058-4838","type":"print"},{"value":"1537-6591","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2021,10,15]]},"published":{"date-parts":[[2021,6,11]]}}}